Prospective Observational Study Aimed at Evaluating Treatment Satisfaction and Effectiveness in Patients with Relapsing Multiple Sclerosis Starting CLADRibinE TAbLets (CLADREAL)

17/10/2022
02/05/2024
EU PAS number:
EUPAS49334
Study
Ongoing
Documents
Study protocol
Study results
Study report
Other information